Avoro Capital Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Avoro Capital Advisors’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-524,321	Closed	-$8.02M	–	62
2018 Q1	$8.02M	Buy	+524,321	New	+$8.17M	0.38%	32
2015 Q2	–	Sell	-475,000	Closed	-$6.87M	–	41
2015 Q1	$6.87M	Buy	+475,000	New	+$7.27M	2.64%	14

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Avoro Capital Advisors's STML Position: Q2 2018 in Review

Avoro Capital Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q2 2018, closing a stake of 524,321 shares — an estimated $8.02M sold.

Avoro Capital Advisors first reported a position in STML in Q1 2015 and held it in 2 quarters. The position peaked at $8.02M in Q1 2018. 91 funds tracked by Wall St. Rank hold STML as of Q2 2018.

Avoro Capital Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Avoro Capital Advisors sold 524,321 Stemline Therapeutics, Inc. shares in Q2 2018, an estimated $8.02M.
Avoro Capital Advisors first reported a position in Stemline Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
Avoro Capital Advisors's Stemline Therapeutics, Inc. position peaked at $8.02M in Q1 2018.
91 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2018.

Based on Avoro Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.